Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study

被引:25
作者
Crabb, Simon J. [1 ]
Bajdik, Chris D. [2 ]
Leung, Samuel [3 ]
Speers, Caroline H. [4 ]
Kennecke, Hagen [1 ]
Huntsman, David G. [3 ]
Gelmon, Karen A. [1 ]
机构
[1] British Columbia Canc Agcy, Dept Med Oncol, Vancouver, BC V5Z 4E6, Canada
[2] British Columbia Canc Agcy, Canc Control Res Program, Vancouver, BC V5Z 1L3, Canada
[3] Univ British Columbia, Genet Pathol Evaluat Ctr, Vancouver, BC V5Z 4E6, Canada
[4] British Columbia Canc Agcy, Breast Canc Outcomes Unit, Vancouver, BC V5Z 4E6, Canada
来源
BREAST CANCER RESEARCH | 2008年 / 10卷 / 01期
关键词
D O I
10.1186/bcr1847
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Introduction Primary breast cancer involving four or more axillary lymph nodes carries a poor prognosis. We hypothesized that use of an immunohistochemical biomarker scoring system could allow for identification of variable risk subgroups. Methods Patients with four or more positive axillary nodes were identified from a clinically annotated tissue microarray of formalin-fixed paraffin-embedded primary breast cancers and randomized into a ' test set' and a ' validation set'. A prospectively defined prognostic scoring model was developed in the test set and was further assessed in the validation set combining expression for eight biomarkers by immunohistochemistry, including estrogen receptor, human epidermal growth factor receptors 1 and 2, carbonic anhydrase IX, cytokeratin 5/ 6, progesterone receptor, p53 and Ki-67. Survival outcomes were analyzed by the Kaplan -Meier method, log rank tests and Cox proportional-hazards models. Results A total of 313 eligible patients were identified in the test set for whom 10-year relapse-free survival was 38.3% (SEM 2.9%), with complete immunohistochemical data available for 227. Tumor size, percentage of positive axillary nodes and expression status for the progesterone receptor, Ki-67 and carbonic anhydrase IX demonstrated independent prognostic significance with respect to relapse-free survival. Our combined biomarker scoring system defined three subgroups in the test set with mean 10-year relapse-free survivals of 75.4% (SEM 7.0%), 35.3% (SEM 4.1%) and 19.3% (SEM 7.0%). In the validation set, differences in relapse-free survival for these subgroups remained statistically significant but less marked. Conclusion Biomarkers assessed here carry independent prognostic value for breast cancer with four or more positive axillary nodes and identified clinically relevant prognostic subgroups. This approach requires refinement and validation of methodology.
引用
收藏
页数:11
相关论文
共 36 条
[1]
High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses [J].
Abd El-Rehim, DM ;
Ball, G ;
Pinder, SE ;
Rakha, E ;
Paish, C ;
Robertson, JFR ;
Macmillan, D ;
Blamey, RW ;
Ellis, IO .
INTERNATIONAL JOURNAL OF CANCER, 2005, 116 (03) :340-350
[2]
Altman DG, 2000, STAT MED, V19, P453, DOI 10.1002/(SICI)1097-0258(20000229)19:4<453::AID-SIM350>3.3.CO
[3]
2-X
[4]
Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial [J].
Bogaerts, Jan ;
Cardoso, Fatima ;
Buyse, Marc ;
Braga, Sofia ;
Loi, Sherene ;
Harrison, Jillian A. ;
Bines, Jacques ;
Mook, Stella ;
Decker, Nuria ;
Ravdin, Peter ;
Therasse, Patrick ;
Rutgers, Emiel ;
van't Veer, Laura J. ;
Piccart, Martine .
NATURE CLINICAL PRACTICE ONCOLOGY, 2006, 3 (10) :540-551
[5]
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer [J].
Buyse, Marc ;
Loi, Sherene ;
van't Veer, Laura ;
Viale, Giuseppe ;
Delorenzi, Mauro ;
Glas, Annuska M. ;
d'Assignies, Mahasti Saghatchian ;
Bergh, Jonas ;
Lidereau, Rosette ;
Ellis, Paul ;
Harris, Adrian ;
Bogaerts, Jan ;
Therasse, Patrick ;
Floore, Arno ;
Amakrane, Mohamed ;
Piette, Fanny ;
Rutgers, Emiel ;
Sotiriou, Christos ;
Cardoso, Fatima ;
Piccart, Martine J. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (17) :1183-1192
[6]
Identification and validation of prognostic markers in breast cancer with the complementary use of array-CGH and tissue microarrays [J].
Callagy, G ;
Pharoah, P ;
Chin, SF ;
Sangan, T ;
Daigo, Y ;
Jackson, L ;
Caldas, C .
JOURNAL OF PATHOLOGY, 2005, 205 (03) :388-396
[7]
Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index [J].
Callagy, GM ;
Pharoah, PD ;
Pinder, SE ;
Hsu, FD ;
Nielsen, TO ;
Ragaz, J ;
Ellis, IO ;
Huntsman, D ;
Caldas, C .
CLINICAL CANCER RESEARCH, 2006, 12 (08) :2468-2475
[8]
CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO
[9]
2-H
[10]
Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma [J].
Chia, SK ;
Wykoff, CC ;
Watson, PH ;
Han, C ;
Leek, RD ;
Pastorek, J ;
Gatter, KC ;
Ratcliffe, P ;
Harris, AL .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) :3660-3668